Anti-inflammatory effects of inhaled corticosteroids in chronic obstructive pulmonary disease: Similarities and differences to asthma

Expert Opinion on Investigational Drugs

Volumn 14, Issue 5, 2005, Pages 619-632

  Jeffery, Peter ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Airway inflammation; Anti inflammatory; Asthma; COPD; Exacerbations; Glucocorticosteroids; Inhaled corticosteroids

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; LONG ACTING DRUG; PLACEBO; SALMETEROL; STEROID; TRIAMCINOLONE;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; CANDIDIASIS; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; EOSINOPHILIA; FRACTURE; HOARSENESS; HUMAN; INFLAMMATORY CELL; LOW DRUG DOSE; LUNG FUNCTION TEST; MAST CELL; MONOTHERAPY; PATHOGENESIS; PATHOPHYSIOLOGY; QUALITY OF LIFE; RESPIRATORY TRACT INFLAMMATION; REVIEW; SKIN BRUISING; SMOKING CESSATION; T LYMPHOCYTE; THROAT DISEASE;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ANIMALS; ANTI-INFLAMMATORY AGENTS; ASTHMA; HUMANS; INFLAMMATION MEDIATORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 20344379422     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.5.619     Document Type: Review

References (113)

1. JEFFERY PK: Remodeling in asthma and chronic obstructive lung disease. Am. J. Respir. Crit. Care Med. (2001) 164(10 Part 2):S28-S38.
2. GINA: Global initiative for asthma. Global Strategy for Asthma Management and Prevention. (2004).
3. MURRAY CJL, LOPEZ AD: Alternative visions of the future: projecting mortality and disability. In: The global burden of disease. Murray CJ et al. (Eds) Harvard University Press, Harvard, USA (1996):361-375.
4. SNIDER GL: Defining chronic obstructive pulmonary disease. In: Chronic Obstructive Pulmonary Disease. Calverley P et al. (Eds) Chapman and Hall, London, UK (1995):1-16.
5. CALVERLEY PM: Inhaled corticosteroids are beneficial in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2000) 161(2 Part 1):341-342 (Discussion 344).
6. BARNES PJ: Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2000) 161(2 Part 1):342-344 (Discussion 344).
7. GOLD: Global strategy for the diagnosis, management and prevention of COPD: 2003 update. Eur. Respir. J. (2003) 22(1):1-2.
8. STEURER-STEY C, BACHMANN LM, STEURER J, TRAMER MR: Oral purified bacterial extracts in chronic bronchitis and COPD: systematic review. Chest (2004) 126(5):1645-1655.
9. JEFFERY PK, WARDLAW AJ, NELSON FC, COLLINS JV, KAY AB: Bronchial biopsies in asthma. An ultrastructural, quantitative study and correlation with hyperreactivity. Am. Rev. Respir. Dis. (1989) 140(6):1745-1753.
10. BOUSQUET J, JEFFERY PK, BUSSE WW, JOHNSON M, VIGNOLA AM: Asthma. From bronchoconstriction to airways inflammation and remodeling. Am. J. Respir. Crit. Care Med. (2000) 161(5):1720-1745.
11. RABE KF, MUNOZ NM, VITA AJ et al.: Contraction of human bronchial smooth muscle caused by activated human eosinophils. Am. J. Physiol. (1994) 267(3 Part 1):L326-L334.
12. COLLINS DS, DUPUIS R, GLEICH GJ et al.: Immunoglobulin E-mediated increase in vascular permeability correlates with eosinophilic inflammation. Am. Rev. Respir. Dis. (1993) 147(3):677-683.
13. LEFF AR: Inflammatory mediation of airway hyperresponsiveness by peripheral blood granulocytes. The case for the eosinophil. Chest (1994) 106(4):1202-1208.
14. ROBINSON DS: Cytokines 3: cytokines in asthma. Thorax (2003) 48:845-853.
15. KIPS JC: Cytokines in asthma. Eur. Respir. J. Suppl. (2001) 34:24s-33s.
16. BRIGHTLING CE, BRADDING P, SYMON FA et al.: Mast-cell infiltration of airway smooth muscle in asthma. N. Engl. J. Med. (2002) 346(22):1699-1705.
17. 1. Am. J. Respir. Crit. Care Med. (1997) 155(3):852-857.
18. HOGG JC, CHU F, UTOKAPARCH S et al.: The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. (2004) 350(26):2645-2653.
19. KEATINGS VM, COLLINS PD, SCOTT DM, BARNES PJ: Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am. J. Respir. Crit. Care Med. (1996) 153(2):530-534.
20. WOOLHOUSE IS, BAYLEY DL, STOCKLEY RA: Sputum chemotactic activity in chronic obstructive pulmonary disease: effect of α(1)-antitrypsin deficiency and the role of leukotriene B(4) and interleukin 8. Thorax (2002) 57(8):709-714.
21. + lymphocytes in patients with COPD. Chest (2004) 125(1):71-76.
22. 1 in smokers are associated with increased levels of sputum neutrophils. Thorax (1996) 51(3):267-271.
23. DE BOER WI, VAN SCHADEWIJK A, SONT JK et al.: Transforming growth factor β1 and recruitment of macrophages and mast cells in airways in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (1998) 158(6):1951-1957.
24. DI STEFANO A, CARAMORI G, CAPELLI A et al.: STAT4 activation in smokers and patients with chronic obstructive pulmonary disease. Eur. Respir. J. (2004) 24(1):78-85.
25. SAETTA M, TURATO G, MAESTRELLI P, MAPP CE, FABBRI LM: Cellular and structural bases of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2001) 163(6):1304-1309.
26. LANG MR, FIAUX GW, GILLOOLY M et al.: Collagen content of alveolar wall tissue in emphysematous and non-emphysematous lungs. Thorax (1994) 49(4):319-326.
27. JEFFERY PK: Differences and similarities between chronic obstructive pulmonary disease and asthma. Clin. Exp. Allergy (1999) 29(Suppl. 2):14-26.
28. TURATO G, ZUIN R, MINIATI M et al.: Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema. Am. J. Respir. Crit. Care Med. (2002) 166(1):105-110.
29. DI STEFANO A, CAPELLI A, LUSUARDI M et al.: Decreased T lymphocyte infiltration in bronchial biopsies of subjects with severe chronic obstructive pulmonary disease. Clin. Exp. Allergy (2001) 31(6):893-902.
30. DI STEFANO A, CAPELLI A, LUSUARDI M et al.: Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am. J. Respir. Crit. Care Med. (1998) 158(4):1277-1285.
31. RETAMALES I, ELLIOTT WM, MESHI B et al.: Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am. J. Respir. Crit. Care Med. (2001) 164(3):469-473.
32. DI STEFANO A, CARAMORI G, RICCIARDOLO FL et al.: Cellular and molecular mechanisms in chronic obstructive pulmonary disease: an overview. Clin. Exp. Allergy (2004) 34(8):1156-1167.
33. JATAKANON A, UASUF C, MAZIAK W et al.: Neutrophilic inflammation in severe persistent asthma. Am. J. Respir. Crit. Care Med. (1999) 160(5 Part 1):1532-1539.
34. WENZEL SE, SZEFLER SJ, LEUNG DY et al.: Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am. J. Respir. Crit. Care Med. (1997) 156(3 Part 1):737-743.
35. RODRIGUEZ-ROISIN R: Toward a consensus definition for COPD exacerbations. Chest (2000) 117(5 Suppl. 2):398S-401S.
36. H1-type (interleukin 2 and interferon gamma) cytokines in bronchoalveolar lavage and bronchial biopsies from atopic asthmatic and normal control subjects. Am. J. Respir. Cell Mol. Biol. (1995) 12(5):477-487.
37. HUMBERT M, YING S, CORRIGAN C et al.: Bronchial mucosal expression of the genes encoding chemokines RANTES and MCP-3 in symptomatic atopic and nonatopic asthmatics: relationship to the eosinophil-active cytokines interleukin (IL)-5, granulocyte macrophage-colony-stimulating factor, and IL-3. Am. J. Respir. Cell Mol. Biol. (1997) 16(1):1-8.
38. YING S, ROBINSON DS, MENG Q et al.: Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant colocalization of eotaxin mRNA to bronchial epithelial and endothelial cells. Eur. J. Immunol. (1997) 27(12):3507-3516.
39. LACOSTE JY, BOUSQUET J, CHANEZ P et al.: Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. (1993) 92(4):537-548.
40. ZHU J, MAJUMDAR S, QIU Y et al.: Interleukin-4 and interleukin-5 gene expression and inflammation in the mucus-secreting glands and subepithelial tissue of smokers with chronic bronchitis. Lack of relationship with CD8(+) cells. Am. J. Respir. Crit. Care Med. (2001) 164(12):2220-2228.
41. MULLEN JB, WRIGHT JL, WIGGS BR, PARE PD, HOGG JC: Reassessment of inflammation of airways in chronic bronchitis. Br. Med. J. (Clin. Res. Ed.) (1985) 291(6504):1235-1239.
42. SAETTA M, DI STEFANO A, MAESTRELLI P et al.: Airway eosinophilia in chronic bronchitis during exacerbations. Am. J. Respir. Crit. Care Med. (1994) 150(6 Part 1):1646-1652.
43. ZHU J, QIU YS, MAJUMDAR S et al.: Exacerbations of Bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants. Am. J. Respir. Crit. Care Med. (2001) 164(1):109-116.
44. BHOWMIK A, SEEMUNGAL TA, SAPSFORD RJ, WEDZICHA JA: Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax (2000) 55(2):114-120.
45. SETHI S: Infectious etiology of acute exacerbations of chronic bronchitis. Chest (2000) 117(5 Suppl. 2):380S-385S.
46. LLOYD CM, DELANEY T, NGUYEN T et al.: CC chemokine receptor (CCR)3/eotaxin is followed by CCR4/monocyte-derived chemokine in mediating pulmonary T helper lymphocyte Type 2 recruitment after serial antigen challenge in vivo. J. Exp. Med. (2000) 191(2):265-274.
47. HADIDA F, VIEILLARD V, MOLLET L et al.: Cutting edge: RANTES regulates Fas ligand expression and killing by HIV-specific CD8 cytotoxic T cells. J. Immunol. (1999) 163(3):1105-1109.
48. KIM JJ, NOTTINGHAM LK, SIN JI et al.: CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines. J. Clin. Invest. (1998) 102(6):1112-1124.
49. JEFFERY P: Lymphocytes, chronic bronchitis and chronic obstructive pulmonary disease. In: Chronic Obstructive Pulmonary Disease. Chadwick D, Goode JA (Eds) (2001) JA Wiley & Sons, Chichester, UK: 149-168.
50. MURPHY TF, SETHI S: Bacterial infection in chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. (1992) 146(4):1067-1083.
51. QIU Y, ZHU J, BANDI V et al.: Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2003) 168(8):968-975.
52. SUR S, CROTTY TB, KEPHART GM et al.: Sudden-onset fatal asthma. A distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa? Am. Rev. Respir. Dis. (1993) 148(3):713-719.
53. AARON SD, ANGEL JB, LUNAU M et al.: Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2001) 163(2)349-355.
54. FAHY JV, KIM KW, LIU J, BOUSHEY HA. Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J. Allergy Clin. Immunol. (1995) 95(4):843-852.
55. LAMBLIN C, GOSSET P, TILLIE-LEBLOND I et al.: Bronchial neutrophilia in patients with noninfectious status asthmaticus. Am. J. Respir. Crit. Care Med. (1998) 157(2):394-402.
56. ORDONEZ CL, SHAUGHNESSY TE, MATTHAY MA, FAHY JV: Increased neutrophil numbers and IL-8 levels in airway secretions in acute severe asthma: Clinical and biologic significance. Am. J. Respir. Crit. Care Med. (2000) 161(4 Part 1): 1185-1190.
57. BARNES PJ, PEDERSEN S, BUSSE W: Efficacy and safety of inhaled corticosteroids: new developments. Am. J. Respir. Crit. Care Med. (1998) 157(3 Suppl. 2):S1-S53.
58. SCHWIEBERT LM, BECK LA, STELLATO C et al.: Glucocorticosteroid inhibition of cytokine production: relevance to antiallergic actions. J. Allergy Clin. Immunol. (1996) 97(1 Part 2):143-152.
59. 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J. Allergy Clin. Immunol. (1992) 90(1):32-42.
60. DJUKANOVIC R, WILSON JW, BRITTEN KM et al.: Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am. Rev. Respir. Dis. (1992) 145(3):669-674.
61. FAUL JL, LEONARD CT, BURKE CM, TORMEY VJ, POULTER LW: Fluticasone propionate induced alterations to lung function and the immunopathology of asthma over time. Thorax (1998) 53(9):753-761.
62. WANG JH, DEVALLA JL, SAPSTORD RJ, DAVIES RJ: Effect of corticosteroids on release of RANTES and sICAM-1 from cultured human bronchial epithelial cells, induced by TNF-α. Eur. Respir. J. (1997) 10(4):834-840.
63. MacFARLANE: BDP prevents the rise in epithelial RANTES after allergen challenge. Am. J. Respir. Crit. Care Med. (2000) 161:A834.
64. KHARITONOV SA, DONNELLY LE, MONTUSCHI P et al.: Dose-dependent onset and cessation of action of inhaled budesonide on exhaled nitric oxide and symptoms in mild asthma. Thorax (2002) 57(10):889-896.
65. KETCHELL RI, JENSEN MW, LUMLEY P et al.: Rapid effect of inhaled fluticasone propionate on airway responsiveness to adenosine 5′-monophosphate in mild asthma. J. Allergy Clin. Immunol. (2002) 110(4):603-606.
66. BARNES PJ, ITO K, ADCOCK IM: Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet (2004) 363(9410):731-733.
67. PAREDI P, KHARITONOV SA, BARNES PJ: Analysis of expired air for oxidation products. Am. J. Respir. Crit. Care Med. (2002) 166(12 Part 2):S31-S37.
68. MONTUSCHI P, COLLINS JV, CIABATTONI G et al.: Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am. J. Respir. Crit. Care Med. (2000) 162 (3 Part 1): 1175-1177.
69. MATTHEWS JG, ITO K, BARNES PJ, ADCOCK IM: Defective glucocorticoid receptor nuclear translocation and altered histone acetylation patterns in glucocorticoid-resistant patients. J. Allergy Clin. Immunol. (2004) 113(6):1100-1108.
70. 2-adrenergic receptor to different G proteins by protein kinase A. Nature (1997) 390(6655):88-91.
71. 2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J. Biol. Chem. (1999) 274(2):1005-1010.
72. ROTH M, RUDIGER J, BIHL M: The β-agonist formoterol activates the glucocorticoid receptor in vivo. Eur. Respir. J. (2000) 16(437s).
73. USMANI OS, MANEECHOTESUWAN K, ADCOCK IM, BARNES PJ: Glucocorticoid receptor activation following inhaled fluticasone and salmeterol. Am. J. Respir. Crit. Care Med. (2002) 165(8):C57.
74. CONFALONIERI M, MAINARDI E, DELLA PORTA R et al.: Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Thorax (1998) 53(7):583-585.
75. YILDIZ F, KAUR AC, ILGAZLI A et al.: Inhaled corticosteroids may reduce neutrophilic inflammation in patients with stable chronic obstructive pulmonary disease. Respiration (2000) 67(1):71-76.
76. BALBI B, MAJORI M, BERTACCO S et al.: Inhaled corticosteroids in stable COPD patients: do they have effects on cells and molecular mediators of airway inflammation? Chest (2000) 117(6):1633-1637.
77. FUKAKUSA M, BERGERON C, TULIC MK et al.: Oral corticosteroids decrease eosinophil and CC chemokine expression but increase neutrophil, IL-8, and IFN-γ-inducible protein 10 expression in asthmatic airway mucosa. J. Allergy Clin. Immunol. (2005) 115(2):280-286.
78. GIZYCKI MJ, HATTOTUWA KL, BARNES N, JEFFERY PK: Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax (2002) 57(9):799-803.
79. HATTOTUWA KL, GIZYCKI MJ, ANSARI TW, JEFFERY PK, BARNES NC: The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am. J. Respir. Crit. Care Med. (2002) 165(12):1592-1596.
80. VERHOEVEN GT, HEGMANS JPJJ, MULDER PGH, HOOGSTEDEN HC, PRINS JB: Effect of an inhaled glucocorticosteroid, fluticasone propionate (FP) on inflammation in bronchial biopsies of COPD patients with bronchial hyperresponsiveness (BHR). Am. J. Respir. Crit. Care Med. (1999) 159:A524.
81. HOOGSTEDEN HC, VERHOEVEN GT, LAMBRECHT BN, PRINS JB: Airway inflammation in asthma and chronic obstructive pulmonary disease with special emphasis on the antigen-presenting dendritic cell: influence of treatment with fluticasone propionate. Clin. Exp. Allergy (1999) 29(Suppl. 2):116-124.
82. LLEWELLYN-JONES CG, HARRIS TA, STOCKLEY RA: Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema. Am. J. Respir. Crit. Care Med. (1996) 153(2):616-621.
83. VERHOEVEN GT, GARRELDS IM, HOOGSTEDEN HC, ZIJLSTRA FJ: Effects of fluticasone propionate inhalation on levels of arachidonic acid metabolites in patients with chronic obstructive pulmonary disease. Mediators Inflamm. (2001) 10(1):21-26.
84. SEETO LJ, BURGESS JK, JOHNSON PR: Effect of fluticasone and salmeterol on human alveolar macrophage cytokine production in patients with chronic obstructive pulmonary disease (COPD). Am. J. Resp. Crit. Care Med. (2003) 167(7):A318.
85. HOTCHKISS JA, HILASKI R, CHO H et al.: Fluticasone propionate attenuates ozone-induced rhinitis and mucous cell metaplasia in rat nasal airway epithelium. Am. J. Respir. Cell Mol. Biol. (1998) 18(1)91-99.
86. BLYTH DI, PEDRICK MS, SAVAGE TJ et al.: Induction, duration, and resolution of airway goblet cell hyperplasia in a routine model of atopic asthma: effect of concurrent infection with respiratory syncytial virus and response to dexamethasone. Am. J. Respir. Cell Mol. Biol. (1998) 19(1):38-54.
87. BTS: BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS. Thorax (1997) 52(Suppl. 5):S1-S28.
88. NIH: National Institutes of Health. Guidelines for the diagnosis and management of asthma, 1997, updated in 2002. (2002)
89. PEDERSEN S, HANSEN OR: Budesonide treatment of moderate and severe asthma in children: a dose-response study. J. Allergy Clin. Immunol. (1995) 95(1 Part 1):29-33.
90. MacKENZIE CA, WEINBERG EG, TABACHNIK E et al.: A placebo controlled trial of fluticasone propionate in asthmatic children. Eur. J. Pediatr. (1993) 152(10):856-860.
91. PAGGIARO PL, DAHLE R, BAKRAN I et al.: Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet (1998) 351(9105):773-780.
92. BURGE PS, CALVERLEY PM, JONES PW et al.: Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br. Med. J. (2000) 320(7245):1297-1303.
93. WEINER P, WEINER M, AZGAD Y, ZAMIR D: Inhaled budesonide therapy for patients with stable COPD. Chest (1995) 108(6):1568-1571.
94. WEINER P, WEINER M, RABNER M et al.: The response to inhaled and oral steroids in patients with stable chronic obstructive pulmonary disease. J. Intern. Med. (1999) 245(1):83-89.
95. VESTBO J, SORENSEN T, LANGE P et al.: Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (1999) 353(9167):1819-1823.
96. PAUWELS RA, LOFDAHL CG, LAITINEN LA et al: Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N. Engl. J. Med. (1999) 340(25):1948-1953.
97. WOUTERS EFE: One year withdrawal of fluticasone after three month treatment with combined fluticasone/salmeterol in COPD. Am. J. Resp. Crit. Care Med. (2004) 169(7):A519.
98. LUNG HEALTH STUDY RESEARCH GROUP: Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N. Engl. J. Med. (2000) 343(26):1902-1909.
99. SIN DD, TU JV: Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2001) 164(4):580-584.
100. SORIANO JB, KIRI VA, PRIDE NB, VESTBO J: Inhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients. Am. J. Respir. Med. (2003) 2(1):67-74.
101. VESTBO J: The TORCH (towards a revolution in COPD health) survival study protocol. Eur. Respir. J. (2004) 24(2):206-210.
102. KNOBIL K, WATKIN S, YATES J, DARKEN P, WIRE P: Fracture incidence from clinical trials of fluticasone propionate alone or in combination with salmeterol in the treatment of chronic obstructive pulmonary disease. Chest (2002) 122(Suppl. 4):43s.
103. VAN STAA TP, LEUFKENS HG, COOPER C: Use of inhaled corticosteroids and risk of fractures. J. Bone Miner. Res. (2001) 16(3):581-588.
104. SUISSA S, BALTZAN M, KREMER R, ERNST P: Inhaled and nasal corticosteroid use and the risk of fracture. Am. J. Respir. Crit. Care Med. (2004) 169(1):83-88.
105. LEE TA, WEISS KB: Fracture risk associated with inhaled corticosteroid use in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2004) 169(7):855-859.
106. SMEETH L, BOULIS M, HUBBARD R, FLETCHER AE: A population based case-control study of cataract and inhaled corticosteroids. Br. J. Ophthalmol. (2003) 87(10):1247-1251.
107. CALVERLEY P, PAUWELS R, VESTBO J et al.: Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (2003) 361(9356):449-456.
108. MAHLER DA, WIRE P, HORSTMAN D et al.: Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2002) 166(8):1084-1091.
109. HANANIA NA, DARKEN P. HORSTMAN D et al.: The efficacy and safety of fluticasone propionate 250 μg/salmeterol 50 μg combined in the discus inhaler for the treatment of chronic obstrctive pulmonary disease. Chest (2003) 124:834-843.
110. SZAFRANSKI W, CUKIER A, RAMIREZ A et al.: Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. (2003) 21(1):74-81.
111. CALVERLEY PM, BOONSAWAT W, CSEKE Z et al.: Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur. Respir. J. (2003) 22(6):912-919.
112. GAMBLE E, GROOTENDORST DC, BRIGHTLING CE et al.: Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo®) in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2003) 168(8):976-982.
113. GRUMELLI S, CORRY DB, SONG LZ et al.: An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. PLos Med. (2004) 1(1):E8.